Drug Trial Radar · NCT07766005
A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Oct 6, 2026
Primary completion
Oct 2027
Study completion Jun 2028
Sponsor
- Lead sponsor
- Spyre Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 2 study will test whether the investigational medicine, SPY072, improves hidradenitis suppurativa (HS) in adults with moderate to severe disease receiving advanced standard of care treatment. About 150 participants will be assigned by chance to receive either SPY072 or placebo for 16 weeks. Participants will be followed after the treatment period to evaluate safety and how long treatment effects may last.
Conditions
- Hidradenitis Suppurativa (HS)
Interventions
SPY072Drug
Solution for SC injection
PlaceboDrug
Matching placebo for SC injection
bimekizumabDrug
Advanced standard of care
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response 75 (HiSCR75)Time frame: Week 16
Locations
34 sites in 2 countries. Site status is shown where the registry gives one.
Site 117
Birmingham, Alabama · Not yet recruiting
Site 119
Rogers, Arkansas · Not yet recruiting
Site 111
Irvine, California · Recruiting
Site 113
Coral Gables, Florida · Not yet recruiting
Site 115
Atlanta, Georgia · Recruiting
Site 101
Indianapolis, Indiana · Recruiting
Site 100
Bowling Green, Kentucky · Recruiting
Site 116
Owensboro, Kentucky · Recruiting
Site 108
Baton Rouge, Louisiana · Recruiting
Site 103
Boston, Massachusetts · Not yet recruiting
Site 112
Boston, Massachusetts · Not yet recruiting
Site 127
Detroit, Michigan · Not yet recruiting
Site 120
Las Vegas, Nevada · Not yet recruiting
Site 126
Las Vegas, Nevada · Not yet recruiting
Site 102
New York, New York · Recruiting
Site 104
The Bronx, New York · Recruiting
Site 124
Durham, North Carolina · Not yet recruiting
Site 122
Oklahoma City, Oklahoma · Not yet recruiting
Site 109
Mt. Pleasant, South Carolina · Recruiting
Site 125
Nashville, Tennessee · Recruiting
Site 118
Smyrna, Tennessee · Recruiting
Site 114
Prosper, Texas · Recruiting
Site 107
Tyler, Texas · Recruiting
Site 121
Tyler, Texas · Recruiting
Site 123
Murray, Utah · Not yet recruiting
Site 106
Mill Creek, Washington · Recruiting
Site 163
Edmonton, Alberta, Canada · Not yet recruiting
Site 165
Surrey, British Columbia, Canada · Not yet recruiting
Site 164
Winnipeg, Manitoba, Canada · Not yet recruiting
Site 160
Barrie, Ontario, Canada · Not yet recruiting
Site 167
Markham, Ontario, Canada · Not yet recruiting
Site 162
Richmond Hill, Ontario, Canada · Not yet recruiting
Site 166
Québec, Quebec, Canada · Not yet recruiting
Site 161
Saskatoon, Saskatchewan, Canada · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.